Thousands of young people in England are now being offered a two-dose vaccine against meningococcal group B (MenB) disease. The targeted expansion of the national immunisation programme focuses on individuals aged 18 and 19 who are either starting university or higher education, or are already enrolled in such programmes. This initiative aims to provide crucial protection to a demographic identified as being at increased risk due to communal living environments.
Meningococcal group B disease is a serious bacterial infection that can cause meningitis (inflammation of the membranes surrounding the brain and spinal cord) and septicaemia (blood poisoning). Both conditions can develop rapidly and have severe consequences, including permanent disability such as brain damage, limb loss, or even death. Data from Public Health England (now UK Health Security Agency) highlights the significant impact of this disease, particularly on young children and, to a lesser extent, adolescents and young adults.
The decision to expand the MenB vaccine programme follows recommendations from the Joint Committee on Vaccination and Immunisation (JCVI), the independent expert advisory committee that advises UK health departments on immunisation. This group previously advised that while the MenB vaccine is routinely offered to infants, a catch-up programme for older adolescents could be beneficial, particularly for those entering higher education settings where close contact can facilitate the spread of infections.
Eligible individuals will receive the vaccine through their GP surgeries. The full course consists of two doses, administered several weeks apart, to ensure optimal protection. It is crucial for those eligible to complete both doses to maximise the vaccine's effectiveness against the MenB bacteria. NHS England and the UK Health Security Agency have been working to ensure that GP practices are prepared to deliver this expanded programme efficiently.
This latest development builds upon the existing MenB vaccination programme, which has been part of the routine childhood immunisation schedule in the UK since September 2015. The childhood programme has significantly reduced the incidence of MenB disease in infants. Extending this protection to older adolescents acknowledges the changing risk profile as individuals transition to new living and social environments, thereby bolstering overall public health resilience against this dangerous infection.
Parents and eligible young people are encouraged to consult their GP or visit the NHS website for further information regarding eligibility and how to access the vaccine. Early uptake of the vaccine is vital to ensure protection before potential exposure in higher education settings.
Source: GOV.UK